The main modification is the merger of variants formerly in class II and in class III into a single class B that comprises all the common polymorphic G6PD variants, all of which entail the risk of severe neonatal jaundice and of acute haemolytic anaemia triggered by fava beans or drugs. Here, G6PD is linked to non-autoimmune hemolytic anemia.